Ad-Hoc announcements

Ypsomed grows by 21% in the first half of 2025/26 in the core business

12.11.2025 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) continued on its growth trajectory in the first half of the 2025/26 financial year, the Delivery Systems business reached CHF 266.6 million of sales. This represents a 21.0% increase compared to the same period last …

Ypsomed unveils growth roadmap at its Capital Markets Day, as a pure play injection specialist and mission critical part of the pharma value chain

29.09.2025 - 6:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) is set to capture significant growth in multiple existing and emerging drug delivery markets and announces a mid-term ambition to reach total sales between CHF 0.9 and 1.1 billion and an EBIT between CHF 280 and 340 …

Ypsomed sells its diabetes business and grows by over 35%

21.05.2025 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf, 21.05.2025, 07:00 a.m. – Ypsomed (SIX: YPSN) continues its growth trajectory and achieved consolidated sales of CHF 748.9 million in the financial year 2024/25 (prior year: CHF 548.5 million). Adjusted for the divested pen needle and blood …

Ypsomed sells its diabetes care business to TecMed AG to become a pure play self-injection specialist

22.04.2025 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX:YPSN) and TecMed AG (TecMed) have entered into an agreement for the sale of Ypsomed diabetes care business for up to CHF 420 million, including earn-out. TecMed is a company based in Burgdorf, controlled by Willy Michel. …

Ypsomed significantly increases sales and decides to initiate the sale of Diabetes Care

13.11.2024 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) continues its growth trend and achieved consolidated sales of CHF 255.4 million in the first six months of the 2023/24 financial year (previous year: CHF 244.2 million).

Ypsomed significantly increases its operating profit and plans to have two independent business areas

22.05.2024 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) continues its growth trend and achieved consolidated sales of CHF 548.5 million in the financial year 2023/24 (previous year: CHF 497.5 million). Adjusted for the sale of the diabetes specialist DiaExpert, this …

Ypsomed sells its pen needle and BGM business to MTD and invests in the expansion of its Solothurn site

27.03.2024 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf - Ypsomed (SIX: YPSN) and Medical Technology and Devices S.p.A. (MTD) have signed an agreement on the transfer of the pen needle and blood glucose monitoring systems (BGMs) businesses. The transfer to MTD will ensure the long-term supply of …

Ypsomed doubles profits and confirms outlook

15.11.2023 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf, 15.11.2023, 07:00 a.m. – Ypsomed (SIX: YPSN) continues its growth trend and achieved consolidated sales of CHF 255.4 million in the first six months of the 2023/24 financial year (previous year: CHF 244.2 million).

Samuel Künzli, Chief Financial Officer (CFO)

Samuel Künzli succeeds Niklaus Ramseier as CFO and Member of the Executive Board

29.09.2023 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf, 29.09.2023, 7:00 a.m. – Ypsomed (SIX: YPSN) announces a change in its Executive Board. After more than twenty years, Niklaus Ramseier will hand over his functions as Chief Financial Officer (CFO) on 31 March 2024 and will continue to be …

Ypsomed concludes a long-term supply agreement for large quantities of autoinjectors

20.09.2023 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) has concluded a long-term supply agreement with Novo Nordisk for large quantities of autoinjectors. The autoinjectors will be used to administer drugs for the self-treatment in various metabolic indications. Ypsomed is …

Ypsomed doubles profits and confirms outlook

24.05.2023 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) continues its growth trend and achieved consolidated sales of CHF 497.5 million in the 2022/23 financial year (previous year: CHF 464.8 million). Adjusted for the effect of the divestment of DiaExpert, continuing …

Eli Lilly is focusing on its successful drug portfolio and is halting its ambition to enter insulin pump business. Ypsomed remains committed to its US YpsoPump ambitions with a new partner

09.12.2022 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Eli Lilly and Company (NYSE: LLY) has decided to fully focus on its successful drug portfolio. Therefore, Lilly decided to stop the joint project with Ypsomed (SIX: YPSN) to enter the US insulin pump market in 2026. Ypsomed plans to submit …

Ypsomed doubles profits and confirms outlook

16.11.2022 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) is on track and achieved consolidated sales of CHF 244.2 million in the first half of the 2022/23 financial year (previous year: CHF 222.6 million). This corresponds to a growth of 9.7% compared with the previous year. …

Ypsomed leaves DiaExpert in new hands and focuses on own products

28.10.2022 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) and Mediq have signed an agreement on the sale of DiaExpert. DiaExpert is an established specialist and mail-order retailer for the care of people with diabetes in Germany, specialised in insulin pump therapy. With the …

Ypsomed employees wearing protective clothing and goggles inspecting a vial to ensure quality in the manufacture of drug delivery systems.

Ypsomed successfully completes capital increase

24.06.2022 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) has completed the capital increase in the full amount of one million new shares very successfully. The subscription and placement price was set at CHF 122.50 after the expiry of the subscription and placement period, …

Ypsomed announces details of capital increase

14.06.2022 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – The Board of Directors of Ypsomed (SIX: YPSN) decided in its meeting on Monday, 13 June 2022, to carry out a capital increase from authorised capital created by the resolution of the Annual General Meeting on Wednesday, 30 June 2021, in …

Ypsomed increases sales by 15.2% and triples its operating profit

25.05.2022 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) generated a growth in sales of 15.2% in the financial year 2021/22 compared to the previous year and achieved a consolidated turnover of CHF 464.8 million (previous year: CHF 403.7 million). On its continued growth …

Ypsomed is growing and expects a further increase

Changes in the Board of Directors at Ypsomed

18.05.2022 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) announces changes to the Board of Directors. The founder and Chairman of the Board of Directors of the Ypsomed Group Dr. h.c. Willy Michel will not stand for re-election as Chairman and member of the Board of Directors …

Ypsomed is growing and expects a further increase

04.11.2021 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SWX: YPSN) generated a growth in turnover of 11.6% in the first half of 2021/22 compared to the previous year and achieved a consolidated total turnover of CHF 222.6 million. On its continued growth trend, the company achieved an …

Notice

Investors

Ad hoc announcements pursuant to Art. 53 LR

Ypsomed grows by 21% in the first half of 2025/26 in the core business

Ypsomed unveils growth roadmap at its Capital Markets Day, as a pure play injection specialist and mission critical part of the pharma value chain

Ypsomed sells its diabetes business and grows by over 35%

Ypsomed sells its diabetes care business to TecMed AG to become a pure play self-injection specialist

Ypsomed significantly increases sales and decides to initiate the sale of Diabetes Care

Ypsomed significantly increases its operating profit and plans to have two independent business areas

Ypsomed sells its pen needle and BGM business to MTD and invests in the expansion of its Solothurn site

Ypsomed doubles profits and confirms outlook

Samuel Künzli succeeds Niklaus Ramseier as CFO and Member of the Executive Board

Ypsomed concludes a long-term supply agreement for large quantities of autoinjectors

Ypsomed doubles profits and confirms outlook

Eli Lilly is focusing on its successful drug portfolio and is halting its ambition to enter insulin pump business. Ypsomed remains committed to its US YpsoPump ambitions with a new partner

Ypsomed doubles profits and confirms outlook

Ypsomed leaves DiaExpert in new hands and focuses on own products

Ypsomed successfully completes capital increase

Ypsomed announces details of capital increase

Ypsomed increases sales by 15.2% and triples its operating profit

Changes in the Board of Directors at Ypsomed

Ypsomed is growing and expects a further increase

News alert

Your IR contact:

Sam Ghezelbash